ReviewThe Indian journal of medical research2013
Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium.
Review in The Indian journal of medical research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 70 citations in OpenAlex.
- A review of tigecycline resistance in nontuberculous mycobacteria.Molecular biology reports · 2026Review
- Association of Vitamin D Receptor Gene Polymorphism (FokI) with Susceptibility to Musculoskeletal Tuberculosis: A Case-Control Study from Central India.Journal of orthopaedic case reports · 2026Article
- A Lightweight Hybrid Deep Learning Model for Tuberculosis Detection from Chest X-Rays.Diagnostics (Basel, Switzerland) · 2025Article
- Evaluation of cytomorphological examination in the diagnosis of pleural effusion.Clinical and experimental medicine · 2025Article
- Response to treatment and low serum vitamin D levels in North Indian patients with treatment-naive category I and multi-drug resistant pulmonary tuberculosis.Annals of medicine · 2024Article
- Article
- Article
- Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now.Cureus · 2023Review
- Early detection of tuberculosis using hybrid feature descriptors and deep learning network.Polish journal of radiology · 2023Article
- Tuberculosis-Associated Anemia: A Narrative Review.Cureus · 2022Review
- A Novel and Robust Approach to Detect Tuberculosis Using Transfer Learning.Journal of healthcare engineering · 2021Article
- Quinolone-isoniazid hybrids: synthesis and preliminaryMedChemComm · 2019Article
- AntiTbPdb: a knowledgebase of anti-tubercular peptides.Database : the journal of biological databases and curation · 2018Article
- Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa.BMC infectious diseases · 2017Article
- Provider-initiated HIV testing & counselling in incident tuberculosis cases under National TB Programme conditions at a tertiary care teaching hospital in Tirupati, south India.The Indian journal of medical research · 2017Article
- Miliary Tuberculosis.Microbiology spectrum · 2017Review
- Article
- Miliary tuberculosis: A new look at an old foe.Journal of clinical tuberculosis and other mycobacterial diseases · 2016Review
- Multidrug-resistant pulmonary & extrapulmonary tuberculosis: A 13 years retrospective hospital-based analysis.The Indian journal of medical research · 2015Article
- Immunogenicity and safety of early vs delayed BCG vaccination in moderately preterm (31-33 weeks) infants.Human vaccines & immunotherapeutics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, tuberculosis (TB) still remains a major public health problem. India is a high TB burden country contributing to 26 per cent of global TB burden. During 1944-1980, TB became treatable and short-course chemotherapy emerged as the standard of care. When TB elimination seemed possible in the early 1980s, global human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS) pandemic resulted in a resurgence of TB. Widespread occurrence of multidrug-resistant and extensively drug-resistant TB (M/XDR-TB) is threatening to destabilize TB control globally. Atypical clinical presentation still poses a challenge. Disseminated, miliary and cryptic TB are being increasingly recognized. Availability of newer imaging modalities has allowed more efficient localization of lesions and use of image guided procedures has facilitated definitive diagnosis of extrapulmonary TB. Introduction of liquid culture, rapid drug-susceptibility testing (DST), molecular diagnostic methods has helped in rapid detection, speciation and DST profiling of Mycobacterium tuberculosis isolates. While treatment of TB and HIV-TB co-infection has become simpler, efforts are on to shorten the treatment duration. However, drug toxicities and drug-drug interactions still constitute a significant challenge. Recently, there has been better understanding of anti-TB drug-induced hepatotoxicity and its frequent confounding by viral hepatitis, especially, in resource-constrained settings; and immune reconstitution inflammatory syndrome (IRIS) in HIV-TB. Quest for newer biomarkers for predicting a durable cure, relapse, discovery/repurposing of newer anti-TB drugs, development of newer vaccines continues to achieve the goal of eliminating TB altogether by 2050.
Indexed as
Identifiers
23640554PMC3705655W2064740131What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.